A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania

RATIONALE: Lithium is an effective prophylactic and anti-manic treatment in bipolar disorder; however, its use is declining through perceived poor tolerance and toxicity. Lithium inhibits inositol monophosphatase (IMPase), a probable key therapeutic mechanism. The anti-inflammatory drug, ebselen, al...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Psychopharmacology (Berl)
Autors principals: Sharpley, Ann L, Williams, Clare, Holder, Adele A, Godlewska, Beata R, Singh, Nisha, Shanyinde, Milensu, MacDonald, Orla, Cowen, Philip J
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7683468/
https://ncbi.nlm.nih.gov/pubmed/32909076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-020-05654-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars